Antibodies against muscarinic receptors in breast cancer: Agonizing tumor growth

Current Immunology Reviews

Volumn 4, Issue 3, 2008, Pages 176-182

  Fiszman, Gabriel L ^a   Sales, María E ^b  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Autoantibodies; Breast cancer; Muscarinic receptors

Indexed keywords

EID: 54749103932     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339508785160732     Document Type: Review

References (42)

1. Forni G, Lollini P, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res 2000; 60: 2571-75.
2. Burnet F. The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13: 1-27.
3. Croci DO, Zacarías Fluck MF, Rico MJ Rab́inovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007; 56: 1687-1700.
4. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
5. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-7.
6. Sogn JA. Tumor Immunology: the glass is half full. Immunity 1998; 9: 757-63.
7. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 2002; 23: 240-5.
8. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 1996; 17: 39-45.
9. Stauss HJ. Benign autoimmunity to combat malignancy. Chin Exp Immunol 2001; 125: 1-2.
10. Torchilin V, Iakoubov L, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. TRENDS Immunol 2001; 22: 424-7.
11. Bazhin A, Shifrina O, Savchenko M, et al. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer without a loss of vision. Lung Cancer 2001; 34: 99-104.
12. Pradier K García Salas C, Kirchuk R, et al. In: RN Ed. Diagnóstico, tratamiento y seguimiento del cáncer. Pautas en Oncología. Instituto Angel H. Roffo. UBA. Pautas en Oncologia. Tumores de mama 2003; 155-71.
13. DeNardo DG, Coussens LM. Balancing immune response:crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
14. Hansen M, Ostenstad B, Sioud M. The tumor infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001; 98: 12659-64.
15. Fernandez Madrid F. Autoantibodies in breast cancer. Candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005; 230: 187-98.
16. Caulfield MP. Muscarinic receptors - characterization, coupling and function. Pharmacol Ther1993; 58:319-79.
17. Wess J, Eglen RM Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development 2007; 6: 721-33.
18. Paleari L, Grozio A, Cesario A, Russo P. The cholinergic system in cancer. Sem Cancer Biol 2008; 3: 211-7.
19. Ukegawa J, Takeuchi Y, Kusayanagi S, Mitamura K. Growth promoting effects of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol 2003; 129: 272-8.
20. Williams CL. Muscarinic signaling in carcinoma cells. Life Sci 2003; 72: 2173-82.
21. Cellai C, Mattucci R, Vannucchi AM, Paoletti F. Constitutive muscarinic receptors are involved in growth and differentiation of Friend erythroleukemia cells. J Cell Physiol 1999; 178: 333-40.
22. Español A, Eiján A, Mazzoni E, et al. Nitric Oxide Synthase, Arginase and Cyclooxygenase are Involved in Muscarinic Receptors Activation in Different Murine Mammary Adenocarcinoma Cell Lines. Int J Mol Med 2002; 9: 651-7.
23. Rimmaudo L, de la Torre E, Sales ME. mAchR are involved in murine mammary adenocarcinoma cells LMM3 proliferation and angiogenesis. Biochem Biophys Res Commun 2005; 334: 1360-5.
24. Español A, de la Torre E, Fiszman G, Sales ME. Role of non-neuronal cholinergic system in breast cancer progression. Life Sci 2007; 80: 2281-5.
25. Goin JC, Nathanson N. Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. J Biol Chem 2006; 281: 5416-25.
26. Park PS, Wells J. Oligomeric potential of the M2 muscarinic cholinergic receptor. J Neurochem 2004; 90: 537-48.
27. Fiszman GL, Middonno MC, de la Torre E, Farina M, Español AJ, Sales ME. Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol Ther 2007; 6: 1106-13.
28. Jiménez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-86.
29. Frucht H, Jensen RT, Dexter D, Yang WL, Xiao YHuman colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clin Cancer Res 1999; 5: 2532-9.
30. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005; 153: 49-55.
31. Weleber R, Watzke R, Shults W, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 2005; 139: 780-94.
32. Tan EM. Autoantibodies as reporters identitying aberrant cellular mechanisms in tumorigenesis. Cencer Res 2000; 60: 1777-88.
33. Whitford PGW, Cambell AM. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett 1992; 61: 157-64.
34. Wen Y, Mancino A, Pashov A, Whitehead T, Stanley J, Kieber-Emmons T. Antigen binding of human IgG Fabs mediates ERK-associated proliferation of human breast cancer cells. DNA Cell Biol 2005; 24: 73-84.
35. Wernicke M. Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. Surg Gynecol Obstet 1975; 140: 919-24.
36. Morton BA, Ramey WG, Paderon H, Miller ME. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res 1986, 46: 2121-6.
37. Fiszman G, Cattaneo V, de la Torre E, et al. Muscarinic receptors autoantibodies purified from mammary adenocarcinoma-bearing mice sera stimulate tumor progression. Int Immunopharmac 2006; 6: 1323-30.
38. Fiszman G, Cattaneo V, de la Torre E, et al. Autoanticuerpos contra receptores muscarinicos en cancer de mama. Química Viva 2005; 4: 1-17.
39. Hellström KE, Hellström I. Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population. Proc Natl Acad Sci USA 1978; 75: 436-40.
40. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK, Tan EM. Denovo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001; 125: 3-9.
41. Williams CL. Muscarinic signaling in carcinoma cells. Life Sci 2003; 72: 2173-82.
42. Boss A, Oppitz M, Drews M. Muscarinic cholinergic receptors in the human melanoma cell line SK-Mel 28: Modulation of chemotaxis. Clin Exp Dermatol 2005; 30: 557-64.